Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free SYRA Stock Alerts

Syra Health (SYRA) Financials

Syra Health logo
$0.74 +0.04 (+6.36%)
As of 07/28/2026 03:47 PM Eastern
Compare
Annual Income Statements for Syra Health

Annual Income Statements for Syra Health

This table shows Syra Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.12 -2.94 -3.76 -0.90
Consolidated Net Income / (Loss)		 -2.12 -2.94 -3.76 -0.90
Net Income / (Loss) Continuing Operations		 -2.12 -2.94 -3.76 -0.90
Total Pre-Tax Income 		-2.12 -2.94 -3.76 -0.90
Total Operating Income		 -2.09 -2.89 -3.76 -0.90
Total Gross Profit		 1.06 1.41 1.65 2.49
Total Revenue		 5.62 5.52 7.98 7.23
Operating Revenue		 5.62 5.52 7.98 7.23
Total Cost of Revenue		 4.56 4.10 6.33 4.74
Operating Cost of Revenue		 4.56 4.10 6.33 4.74
Total Operating Expenses		 3.15 4.30 5.42 3.39
Selling, General & Admin Expense		 1.61 1.72 2.05 1.80
Research & Development Expense		 0.00 0.24 0.59 0.07
Depreciation Expense		 0.01 0.05 0.06 0.02
Other Operating Expenses / (Income)		 1.52 2.29 2.72 1.50
Total Other Income / (Expense), net		 -0.03 -0.05 0.01 0.01
Interest Expense		 0.03 0.05 0.02 0.01
Interest & Investment Income		 0.00 0.00 0.02 0.02
Basic Earnings per Share		 ($0.70) ($0.60) ($0.50) ($0.08)
Weighted Average Basic Shares Outstanding		 3.04M 4.88M 7.55M 11.85M
Diluted Earnings per Share		 ($0.70) ($0.60) ($0.50) ($0.08)
Weighted Average Diluted Shares Outstanding		 3.04M 4.88M 7.55M 11.85M
Weighted Average Basic & Diluted Shares Outstanding		 - 5.73M 11.31M 11.34M

Quarterly Income Statements for Syra Health

This table shows Syra Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -0.35 -1.00 -1.45 -1.39 -0.42 -0.50 -0.47 -0.06 -0.23 -0.13 0.24
Consolidated Net Income / (Loss)		 -0.35 -1.00 -1.45 -1.39 -0.42 -0.50 -0.47 -0.06 -0.23 -0.13 0.24
Net Income / (Loss) Continuing Operations		 -0.35 -1.00 -1.45 -1.39 -0.42 -0.50 -0.47 -0.06 -0.23 -0.13 0.24
Total Pre-Tax Income 		-0.35 -1.00 -1.45 -1.39 -0.42 -0.50 -0.47 -0.06 -0.23 -0.13 0.24
Total Operating Income		 -0.34 -0.99 -1.44 -1.39 -0.43 -0.50 -0.47 -0.06 -0.23 -0.14 0.19
Total Gross Profit		 0.55 0.58 0.30 0.35 0.67 0.33 0.59 0.75 0.55 0.59 0.97
Total Revenue		 1.58 1.77 1.75 1.97 2.25 2.01 1.86 1.95 1.69 1.73 2.27
Operating Revenue		 1.58 1.77 1.75 1.97 2.25 2.01 1.86 1.95 1.69 1.73 2.27
Total Cost of Revenue		 1.03 1.18 1.45 1.62 1.59 1.67 1.27 1.19 1.13 1.14 1.30
Operating Cost of Revenue		 1.03 1.18 1.45 1.62 1.59 1.67 1.27 1.19 1.13 1.14 1.30
Total Operating Expenses		 0.90 1.57 1.74 1.74 1.10 0.84 1.06 0.82 0.79 0.73 0.78
Selling, General & Admin Expense		 0.29 0.64 0.72 0.60 0.44 0.29 0.51 0.45 0.44 0.39 0.40
Research & Development Expense		 0.00 0.24 0.28 0.28 0.03 -0.01 0.04 0.03 0.00 0.00 0.01
Depreciation Expense		 0.01 0.01 0.01 0.02 0.03 0.01 0.01 0.01 0.01 0.00 0.00
Other Operating Expenses / (Income)		 0.59 0.68 0.74 0.85 0.59 0.54 0.51 0.33 0.34 0.33 0.37
Total Other Income / (Expense), net		 -0.01 -0.01 -0.00 0.00 0.01 -0.00 0.00 -0.00 0.01 0.00 0.05
Interest Expense		 0.01 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00
Interest & Investment Income		 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.05
Basic Earnings per Share		 ($0.08) ($0.16) ($0.22) ($0.21) ($0.06) ($0.01) ($0.04) ($0.01) ($0.02) ($0.01) $0.02
Weighted Average Basic Shares Outstanding		 4.36M 4.88M 6.50M 6.60M 7.26M 7.55M 11.59M 11.94M 11.94M 11.85M 11.94M
Diluted Earnings per Share		 ($0.08) ($0.16) ($0.22) ($0.21) ($0.06) ($0.01) ($0.04) ($0.01) ($0.02) ($0.01) $0.02
Weighted Average Diluted Shares Outstanding		 4.36M 4.88M 6.50M 6.60M 7.26M 7.55M 11.59M 11.94M 11.94M 11.85M 12.78M
Weighted Average Basic & Diluted Shares Outstanding		 - 5.73M 6.42M 6.61M 8.97M 11.31M 11.34M 11.34M 11.34M 11.34M 11.34M

Annual Cash Flow Statements for Syra Health

This table details how cash moves in and out of Syra Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.10 3.28 -0.88 -0.78
Net Cash From Operating Activities		 -2.24 -2.76 -2.93 -0.45
Net Cash From Continuing Operating Activities		 -2.24 -2.76 -2.93 -0.45
Net Income / (Loss) Continuing Operations		 -2.12 -2.94 -3.76 -0.90
Consolidated Net Income / (Loss)		 -2.12 -2.94 -3.76 -0.90
Depreciation Expense		 0.01 0.05 0.06 0.02
Non-Cash Adjustments To Reconcile Net Income		 0.51 0.03 0.22 0.10
Changes in Operating Assets and Liabilities, net		 -0.67 0.10 0.54 0.33
Net Cash From Investing Activities		 -0.12 -0.02 -0.01 -0.00
Net Cash From Continuing Investing Activities		 -0.12 -0.02 -0.01 -0.00
Purchase of Property, Plant & Equipment		 -0.12 -0.02 -0.01 -0.00
Net Cash From Financing Activities		 2.27 6.05 2.06 -0.33
Net Cash From Continuing Financing Activities		 2.27 6.05 2.06 -0.33
Repayment of Debt		 -2.97 -2.33 -0.41 -0.35
Issuance of Common Equity		 2.32 5.33 2.47 0.01
Cash Interest Paid		 0.01 0.04 0.02 0.01
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Syra Health

This table details how cash moves in and out of Syra Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -0.02 3.26 -0.04 -1.64 1.10 -0.30 0.10 -0.18 -0.33 -0.36 1.31
Net Cash From Operating Activities		 -0.37 -1.76 -0.80 -1.50 -0.41 -0.21 0.16 -0.07 -0.24 -0.29 1.36
Net Cash From Continuing Operating Activities		 -0.37 -1.76 -0.80 -1.50 -0.41 -0.21 0.16 -0.07 -0.24 -0.29 1.36
Net Income / (Loss) Continuing Operations		 -0.35 -1.00 -1.45 -1.39 -0.42 -0.50 -0.47 -0.06 -0.23 -0.13 0.24
Consolidated Net Income / (Loss)		 -0.35 -1.00 -1.45 -1.39 -0.42 -0.50 -0.47 -0.06 -0.23 -0.13 0.24
Depreciation Expense		 0.01 0.01 0.01 0.02 0.03 0.01 0.01 0.01 0.01 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.03 -0.07 0.06 0.07 0.04 0.05 -0.21 0.02 0.02 0.02 0.02
Changes in Operating Assets and Liabilities, net		 -0.06 -0.70 0.57 -0.20 -0.06 0.23 0.83 -0.04 -0.04 -0.18 1.10
Net Cash From Investing Activities		 - - -0.01 -0.01 - - 0.00 - - -0.00 0.00
Net Cash From Continuing Investing Activities		 - - -0.01 -0.01 - - 0.00 - - -0.00 0.00
Purchase of Property, Plant & Equipment		 - - -0.01 -0.01 - - 0.00 - - -0.00 0.00
Net Cash From Financing Activities		 0.35 5.02 0.76 -0.13 1.52 -0.09 -0.06 -0.11 -0.09 -0.07 -0.05
Net Cash From Continuing Financing Activities		 0.35 5.02 0.76 -0.13 1.52 -0.09 -0.06 -0.11 -0.09 -0.07 -0.05
Repayment of Debt		 -0.94 -0.31 -0.09 -0.13 -0.10 -0.09 -0.08 -0.11 -0.09 -0.07 -0.05
Issuance of Common Equity		 - 5.33 - - - - 0.01 - - - 0.00
Cash Interest Paid		 0.01 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 - - 0.00 - - - 0.00 - - - 0.00

Annual Balance Sheets for Syra Health

This table presents Syra Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 2.32 4.92 3.68 2.77
Total Current Assets		 1.43 4.78 3.35 2.74
Cash & Equivalents		 0.00 3.28 2.40 1.61
Accounts Receivable		 1.20 1.11 0.68 0.92
Other Current Assets		 0.22 0.39 0.28 0.21
Plant, Property, & Equipment, net		 0.11 0.08 0.03 0.01
Total Noncurrent Assets		 0.78 0.06 0.30 0.03
Other Noncurrent Operating Assets		 0.78 0.06 0.30 0.03
Total Liabilities & Shareholders' Equity		 2.32 4.92 3.68 2.77
Total Liabilities		 1.61 0.91 0.80 0.67
Total Current Liabilities		 1.55 0.91 0.61 0.67
Short-Term Debt		 0.75 0.18 0.15 0.12
Accounts Payable		 0.44 0.46 0.10 0.32
Accrued Expenses		 0.24 0.20 0.23 0.19
Current Deferred Revenue		 - 0.00 0.02 0.02
Other Current Liabilities		 0.12 0.06 0.11 0.03
Total Noncurrent Liabilities		 0.06 0.00 0.19 0.00
Other Noncurrent Operating Liabilities		 0.06 0.00 0.19 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.71 4.01 2.88 2.10
Total Preferred & Common Equity		 0.71 4.01 2.88 2.10
Preferred Stock		 0.00 0.00 0.00 0.00
Total Common Equity		 0.71 4.01 2.88 2.10
Common Stock		 2.84 9.08 12 12
Retained Earnings		 -2.13 -5.06 -8.82 -9.72

Quarterly Balance Sheets for Syra Health

This table presents Syra Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 4.55 3.24 4.43 3.72 3.47 3.26 3.94
Total Current Assets		 4.45 2.83 4.06 3.65 3.43 3.21 3.93
Cash & Equivalents		 3.24 1.59 2.70 2.49 2.31 1.98 2.92
Accounts Receivable		 0.83 0.84 0.88 0.95 0.89 0.93 0.87
Other Current Assets		 0.38 0.39 0.48 0.21 0.24 0.31 0.14
Plant, Property, & Equipment, net		 0.07 0.06 0.03 0.02 0.01 0.01 0.01
Total Noncurrent Assets		 0.03 0.35 0.33 0.05 0.02 0.04 0.01
Other Noncurrent Operating Assets		 0.03 0.35 0.33 0.05 0.02 0.04 0.01
Total Liabilities & Shareholders' Equity		 4.55 3.24 4.43 3.72 3.47 3.26 3.94
Total Liabilities		 1.10 1.15 1.09 1.27 1.06 1.05 1.58
Total Current Liabilities		 1.10 0.90 0.88 1.27 1.06 1.05 1.58
Short-Term Debt		 0.10 0.11 0.24 0.08 0.09 0.19 0.06
Accounts Payable		 0.65 0.50 0.21 0.33 0.56 0.46 0.46
Accrued Expenses		 0.32 0.17 0.31 0.21 0.12 0.22 0.29
Current Deferred Revenue		 0.01 0.01 0.01 0.60 0.27 0.14 0.75
Other Current Liabilities		 0.03 0.11 0.11 0.05 0.02 0.04 0.01
Total Noncurrent Liabilities		 0.00 0.24 0.22 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 - 0.24 0.22 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3.45 2.09 3.33 2.46 2.41 2.21 2.36
Total Preferred & Common Equity		 3.45 2.09 3.33 2.46 2.41 2.21 2.36
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 3.45 2.09 3.33 2.46 2.41 2.21 2.36
Common Stock		 9.96 9.99 12 12 12 12 12
Retained Earnings		 -6.51 -7.90 -8.32 -9.30 -9.36 -9.59 -9.48

Annual Metrics And Ratios for Syra Health

This table displays calculated financial ratios and metrics derived from Syra Health's official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 8,973,774.00 11,339,169.00
DEI Adjusted Shares Outstanding		 0.00 0.00 8,973,774.00 11,339,169.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.42 -0.08
Growth Metrics		 - - - -
Revenue Growth		 0.00% -1.83% 44.73% -9.47%
EBITDA Growth		 0.00% -37.76% -30.41% 76.13%
EBIT Growth		 0.00% -38.18% -30.38% 75.98%
NOPAT Growth		 0.00% -38.18% -30.38% 75.98%
Net Income Growth		 0.00% -38.72% -27.94% 76.16%
EPS Growth		 0.00% 14.29% 16.67% 84.00%
Operating Cash Flow Growth		 0.00% -22.95% -6.27% 84.73%
Free Cash Flow Firm Growth		 0.00% 0.00% -58.80% 74.64%
Invested Capital Growth		 0.00% -37.00% -30.72% -5.69%
Revenue Q/Q Growth		 0.00% 0.00% 3.11% -3.64%
EBITDA Q/Q Growth		 0.00% 0.00% 11.46% 29.00%
EBIT Q/Q Growth		 0.00% 0.00% 11.40% 28.81%
NOPAT Q/Q Growth		 0.00% 0.00% 11.40% 28.81%
Net Income Q/Q Growth		 0.00% 0.00% 11.55% 29.21%
EPS Q/Q Growth		 0.00% 0.00% 23.08% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 34.47% -19.95%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -36.39%
Invested Capital Q/Q Growth		 0.00% 0.00% -27.18% 42.23%
Profitability Metrics		 - - - -
Gross Margin		 18.90% 25.60% 20.71% 34.43%
EBITDA Margin		 -36.68% -51.47% -46.38% -12.23%
Operating Margin		 -37.20% -52.36% -47.17% -12.51%
EBIT Margin		 -37.20% -52.36% -47.17% -12.51%
Profit (Net Income) Margin		 -37.71% -53.28% -47.10% -12.40%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.36% 101.76% 99.85% 99.12%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -100.38% -170.19% -339.16% -102.44%
ROIC Less NNEP Spread (ROIC-NNEP)		 -188.09% -92.08% -297.05% -88.36%
Return on Net Nonoperating Assets (RNNOA)		 -197.92% 45.77% 230.07% 66.42%
Return on Equity (ROE)		 -298.29% -124.42% -109.09% -36.02%
Cash Return on Invested Capital (CROIC)		 0.00% -124.79% -302.87% -96.58%
Operating Return on Assets (OROA)		 -90.09% -79.74% -87.53% -28.03%
Return on Assets (ROA)		 -91.31% -81.14% -87.40% -27.78%
Return on Common Equity (ROCE)		 -298.29% -124.42% -109.09% -36.02%
Return on Equity Simple (ROE_SIMPLE)		 -298.29% -73.22% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.46 -2.02 -2.64 -0.63
NOPAT Margin		 -26.04% -36.65% -33.02% -8.76%
Net Nonoperating Expense Percent (NNEP)		 87.71% -78.11% -42.11% -14.08%
Return On Investment Capital (ROIC_SIMPLE)		 - -48.15% -86.94% -28.58%
Cost of Revenue to Revenue		 81.10% 74.40% 79.29% 65.57%
SG&A Expenses to Revenue		 28.69% 31.16% 25.70% 24.95%
R&D to Revenue		 0.00% 4.35% 7.33% 0.94%
Operating Expenses to Revenue		 56.10% 77.96% 67.88% 46.94%
Earnings before Interest and Taxes (EBIT)		 -2.09 -2.89 -3.76 -0.90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.06 -2.84 -3.70 -0.88
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 9.39 0.00 1.28 0.46
Price to Tangible Book Value (P/TBV)		 9.39 0.00 1.28 0.46
Price to Revenue (P/Rev)		 1.19 0.00 0.46 0.13
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 5.09 0.00 2.29 0.00
Enterprise Value to Revenue (EV/Rev)		 1.32 0.00 0.18 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 1.06 0.05 0.05 0.06
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00
Financial Leverage		 1.05 -0.50 -0.77 -0.75
Leverage Ratio		 3.27 1.53 1.25 1.30
Compound Leverage Factor		 3.31 1.56 1.25 1.29
Debt to Total Capital		 51.38% 4.40% 5.04% 5.26%
Short-Term Debt to Total Capital		 51.38% 4.40% 5.04% 5.26%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 48.62% 95.60% 94.96% 94.74%
Debt to EBITDA		 -0.36 -0.07 -0.04 -0.13
Net Debt to EBITDA		 -0.36 1.09 0.61 1.70
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.51 -0.09 -0.06 -0.18
Net Debt to NOPAT		 -0.51 1.53 0.85 2.37
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 0.59 0.00 -0.90 -1.62
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 0.92 5.25 5.46 4.06
Quick Ratio		 0.78 4.83 5.01 3.75
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -1.48 -2.35 -0.60
Operating Cash Flow to CapEx		 -1,850.62% -18,091.06% -26,388.56% -418,454.21%
Free Cash Flow to Firm to Interest Expense		 0.00 -27.61 -150.86 -44.97
Operating Cash Flow to Interest Expense		 -78.65 -51.39 -187.95 -33.74
Operating Cash Flow Less CapEx to Interest Expense		 -82.90 -51.68 -188.66 -33.75
Efficiency Ratios		 - - - -
Asset Turnover		 2.42 1.52 1.86 2.24
Accounts Receivable Turnover		 4.68 4.77 8.91 9.04
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 49.94 57.61 150.15 420.93
Accounts Payable Turnover		 10.46 9.13 22.42 22.50
Days Sales Outstanding (DSO)		 78.04 76.52 40.97 40.39
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 34.90 39.97 16.28 16.22
Cash Conversion Cycle (CCC)		 43.14 36.55 24.69 24.17
Capital & Investment Metrics		 - - - -
Invested Capital		 1.46 0.92 0.64 0.60
Invested Capital Turnover		 3.85 4.64 10.27 11.69
Increase / (Decrease) in Invested Capital		 0.00 -0.54 -0.28 -0.04
Enterprise Value (EV)		 7.42 0.00 1.45 -0.53
Market Capitalization		 6.67 0.00 3.70 0.97
Book Value per Share		 $0.23 $0.82 $0.32 $0.19
Tangible Book Value per Share		 $0.23 $0.82 $0.32 $0.19
Total Capital		 1.46 4.20 3.03 2.21
Total Debt		 0.75 0.18 0.15 0.12
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 0.75 -3.10 -2.24 -1.50
Capital Expenditures (CapEx)		 0.12 0.02 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.63 0.78 0.50 0.57
Debt-free Net Working Capital (DFNWC)		 0.63 4.06 2.89 2.18
Net Working Capital (NWC)		 -0.12 3.87 2.74 2.06
Net Nonoperating Expense (NNE)		 0.66 0.92 1.12 0.26
Net Nonoperating Obligations (NNO)		 0.75 -3.10 -2.24 -1.50
Total Depreciation and Amortization (D&A)		 0.03 0.05 0.06 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 11.17% 14.07% 6.22% 7.83%
Debt-free Net Working Capital to Revenue		 11.23% 73.54% 36.23% 30.17%
Net Working Capital to Revenue		 -2.13% 70.19% 34.32% 28.56%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.60) ($0.50) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 4.88M 7.55M 11.85M
Adjusted Diluted Earnings per Share		 $0.00 ($0.60) ($0.50) ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 4.88M 7.55M 11.85M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 5.73M 11.31M 11.34M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.46 -2.02 -2.64 -0.63
Normalized NOPAT Margin		 -26.04% -36.65% -33.02% -8.76%
Pre Tax Income Margin		 -37.71% -53.28% -47.10% -12.40%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 -73.24 -53.79 -241.34 -68.15
NOPAT to Interest Expense		 -51.27 -37.65 -168.94 -47.70
EBIT Less CapEx to Interest Expense		 -77.49 -54.07 -242.05 -68.16
NOPAT Less CapEx to Interest Expense		 -55.52 -37.93 -169.65 -47.71
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Syra Health

This table displays calculated financial ratios and metrics derived from Syra Health's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 0.00 0.00 5,731,587.00 6,421,632.00 6,612,421.00 8,973,774.00 11,312,544.00 11,339,169.00 11,339,169.00 11,339,169.00 11,339,169.00
DEI Adjusted Shares Outstanding		 0.00 0.00 5,731,587.00 6,421,632.00 6,612,421.00 8,973,774.00 11,312,544.00 11,339,169.00 11,339,169.00 11,339,169.00 11,339,169.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.25 -0.22 -0.06 -0.06 -0.04 -0.01 -0.02 -0.01 0.02
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 47.46% 101.14% 42.50% 13.62% 6.02% -1.19% -25.09% -13.59% 22.38%
EBITDA Growth		 0.00% 0.00% -87.67% -77.93% -21.99% 49.23% 67.41% 95.84% 43.78% 73.02% 141.16%
EBIT Growth		 0.00% 0.00% -86.44% -77.35% -25.04% 49.13% 67.22% 95.46% 45.87% 72.96% 140.35%
NOPAT Growth		 0.00% 0.00% -86.44% -77.35% -25.04% 49.13% 67.22% 95.46% 45.87% 72.96% 157.64%
Net Income Growth		 0.00% 0.00% -84.13% -73.18% -17.82% 49.32% 67.36% 95.43% 45.90% 73.32% 151.03%
EPS Growth		 0.00% 0.00% -22.22% -16.67% 25.00% 93.75% 81.82% 95.24% 66.67% 0.00% 150.00%
Operating Cash Flow Growth		 0.00% 0.00% -1,676.99% -155.79% -11.93% 87.78% 119.76% 95.18% 40.89% -34.68% 760.73%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 95.30% 123.53% 124.64% 15.09% 1,276.21%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -30.72% -86.76% -68.16% -51.71% -5.69% -1,311.55%
Revenue Q/Q Growth		 61.49% 11.69% -0.78% 12.40% 14.40% -10.94% -7.42% 4.76% -13.27% 2.73% 31.11%
EBITDA Q/Q Growth		 57.15% -194.50% -46.99% 4.08% 70.62% -22.57% 5.63% 87.74% -296.60% 41.19% 243.99%
EBIT Q/Q Growth		 56.25% -187.50% -46.42% 3.71% 69.15% -16.96% 5.65% 86.66% -267.60% 41.57% 240.78%
NOPAT Q/Q Growth		 56.25% -187.50% -46.42% 3.71% 69.15% -16.96% 5.65% 86.66% -267.60% 41.57% 301.11%
Net Income Q/Q Growth		 55.86% -180.85% -45.39% 3.92% 69.97% -20.80% 6.37% 86.53% -255.21% 40.43% 279.07%
EPS Q/Q Growth		 55.56% -100.00% -37.50% 4.55% 71.43% 83.33% -300.00% 75.00% -100.00% 50.00% 300.00%
Operating Cash Flow Q/Q Growth		 37.17% -375.82% 54.43% -87.73% 72.51% 48.05% 173.69% -145.80% -237.08% -18.37% 570.95%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -20.01% 25.98% 94.11% 10.30% 701.25% -22.50% -120.31% 1,342.51%
Invested Capital Q/Q Growth		 0.00% 0.00% -66.19% 97.27% 42.66% -27.18% -93.54% 374.50% 116.33% 42.23% -182.99%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 35.07% 32.95% 17.11% 17.77% 29.66% 16.69% 31.71% 38.69% 32.85% 34.09% 42.72%
EBITDA Margin		 -20.91% -55.14% -81.69% -69.71% -17.90% -24.64% -25.11% -2.94% -13.43% -7.69% 8.45%
Operating Margin		 -21.69% -55.83% -82.40% -70.59% -19.03% -25.00% -25.48% -3.25% -13.75% -7.82% 8.40%
EBIT Margin		 -21.69% -55.83% -82.40% -70.59% -19.03% -25.00% -25.48% -3.25% -13.75% -7.82% 8.40%
Profit (Net Income) Margin		 -22.41% -56.35% -82.58% -70.58% -18.53% -25.14% -25.42% -3.27% -13.38% -7.76% 10.60%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 103.31% 100.92% 100.21% 99.99% 97.35% 100.54% 99.77% 100.69% 97.30% 99.20% 126.18%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -234.80% -2,259.57% -1,141.09% -236.20% -179.76% -820.82% -45.39% -111.49% -64.04% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -224.95% -2,231.77% -1,084.74% -226.65% -174.02% -815.74% -44.34% -108.50% -61.92% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 173.49% 2,030.96% 767.32% 167.21% 134.78% 767.20% 36.40% 83.14% 46.54% 0.00%
Return on Equity (ROE)		 0.00% -61.31% -228.61% -373.77% -68.98% -44.98% -53.62% -8.99% -28.35% -17.49% -7.60%
Cash Return on Invested Capital (CROIC)		 0.00% -161.44% 0.00% 0.00% 0.00% -302.87% -959.84% -151.05% -67.57% -96.58% 0.00%
Operating Return on Assets (OROA)		 0.00% -85.03% -110.06% -154.10% -66.60% -46.39% -49.81% -7.80% -26.83% -17.52% 16.75%
Return on Assets (ROA)		 0.00% -85.82% -110.29% -154.09% -64.84% -46.64% -49.70% -7.85% -26.11% -17.38% 21.13%
Return on Common Equity (ROCE)		 0.00% -61.31% -228.61% -373.77% -68.98% -44.98% -53.62% -8.99% -28.35% -17.49% -7.60%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -104.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.24 -0.69 -1.01 -0.97 -0.30 -0.35 -0.33 -0.04 -0.16 -0.09 0.19
NOPAT Margin		 -15.18% -39.08% -57.68% -49.41% -13.32% -17.50% -17.84% -2.27% -9.63% -5.48% 8.40%
Net Nonoperating Expense Percent (NNEP)		 0.00% -9.85% -27.80% -56.35% -9.55% -5.74% -5.07% -1.05% -2.99% -2.12% 1.90%
Return On Investment Capital (ROIC_SIMPLE)		 - -16.44% -28.49% -44.11% -8.41% -11.58% -13.09% -1.77% -6.78% -4.29% 7.88%
Cost of Revenue to Revenue		 64.93% 67.05% 82.89% 82.23% 70.34% 83.31% 68.29% 61.31% 67.15% 65.91% 57.28%
SG&A Expenses to Revenue		 18.53% 36.02% 40.94% 30.36% 19.62% 14.64% 27.52% 23.33% 26.31% 22.70% 17.60%
R&D to Revenue		 0.00% 13.59% 15.84% 14.11% 1.55% -0.26% 2.00% 1.53% 0.05% 0.01% 0.30%
Operating Expenses to Revenue		 56.76% 88.79% 99.51% 88.36% 48.69% 41.69% 57.19% 41.93% 46.61% 41.92% 34.32%
Earnings before Interest and Taxes (EBIT)		 -0.34 -0.99 -1.44 -1.39 -0.43 -0.50 -0.47 -0.06 -0.23 -0.14 0.19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.33 -0.97 -1.43 -1.37 -0.40 -0.49 -0.47 -0.06 -0.23 -0.13 0.19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 2.29 4.20 0.84 1.28 1.20 0.51 0.46 0.46 1.03
Price to Tangible Book Value (P/TBV)		 0.00 0.00 2.29 4.20 0.84 1.28 1.20 0.51 0.46 0.46 1.03
Price to Revenue (P/Rev)		 0.00 0.00 1.30 1.24 0.36 0.46 0.36 0.15 0.14 0.13 0.32
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 15.37 11.95 0.40 2.29 12.77 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.78 1.04 0.04 0.18 0.06 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.05 0.03 0.05 0.07 0.05 0.03 0.04 0.09 0.06 0.03
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.77 -0.91 -0.71 -0.74 -0.77 -0.94 -0.82 -0.77 -0.75 -1.09
Leverage Ratio		 0.00 1.53 1.32 1.55 1.33 1.25 1.40 1.49 1.39 1.30 1.59
Compound Leverage Factor		 0.00 1.55 1.32 1.55 1.29 1.26 1.40 1.50 1.35 1.29 2.01
Debt to Total Capital		 0.00% 4.40% 2.79% 5.18% 6.73% 5.04% 2.96% 3.47% 7.88% 5.26% 2.56%
Short-Term Debt to Total Capital		 0.00% 4.40% 2.79% 5.18% 6.73% 5.04% 2.96% 3.47% 7.88% 5.26% 2.56%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 95.60% 97.21% 94.82% 93.27% 94.96% 97.04% 96.53% 92.12% 94.74% 97.44%
Debt to EBITDA		 0.00 -0.07 -0.03 -0.03 -0.06 -0.04 -0.03 -0.06 -0.15 -0.13 -0.28
Net Debt to EBITDA		 0.00 1.09 0.89 0.36 0.59 0.61 0.88 1.56 1.44 1.70 12.70
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.09 -0.04 -0.04 -0.08 -0.06 -0.04 -0.08 -0.21 -0.18 -0.37
Net Debt to NOPAT		 0.00 1.53 1.26 0.51 0.83 0.85 1.24 2.16 2.01 2.37 17.03
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 3.47 2.67 1.20 2.02 0.42 0.01 -0.68 -0.71 0.37
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 5.25 4.04 3.14 4.63 5.46 2.88 3.25 3.05 4.06 2.48
Quick Ratio		 0.00 4.83 3.69 2.70 4.08 5.01 2.71 3.02 2.75 3.75 2.40
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 -1.32 -1.59 -1.17 -0.07 -0.06 0.37 0.29 -0.06 0.73
Operating Cash Flow to CapEx		 0.00% 0.00% -14,250.67% -27,371.94% 0.00% 0.00% 0.00% 0.00% 0.00% -270,272.90% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -324.05 -425.18 -517.94 -12.51 -19.22 96.70 151.79 -13.73 296.45
Operating Cash Flow to Interest Expense		 -26.04 -190.22 -196.41 -403.13 -182.39 -38.84 49.00 -18.79 -128.25 -67.60 553.19
Operating Cash Flow Less CapEx to Interest Expense		 -26.04 -190.22 -197.78 -404.60 -182.39 -38.84 49.00 -18.79 -128.25 -67.62 553.19
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 1.52 1.34 2.18 3.50 1.86 1.95 2.40 1.95 2.24 1.99
Accounts Receivable Turnover		 0.00 4.77 7.34 8.40 0.00 8.91 9.12 9.33 8.28 9.04 8.42
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 57.61 84.38 117.50 0.00 150.15 174.68 215.79 342.40 420.93 577.13
Accounts Payable Turnover		 0.00 9.13 6.99 10.56 0.00 22.42 12.66 10.82 15.77 22.50 12.08
Days Sales Outstanding (DSO)		 0.00 76.52 49.70 43.45 0.00 40.97 40.02 39.10 44.07 40.39 43.35
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 39.97 52.19 34.55 0.00 16.28 28.82 33.74 23.15 16.22 30.21
Cash Conversion Cycle (CCC)		 0.00 36.55 -2.49 8.90 0.00 24.69 11.20 5.37 20.92 24.17 13.13
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 0.92 0.31 0.61 0.87 0.64 0.04 0.19 0.42 0.60 -0.50
Invested Capital Turnover		 0.00 6.01 39.17 23.09 17.73 10.27 46.02 19.98 11.58 11.69 -33.46
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.31 0.61 0.87 -0.28 -0.27 -0.42 -0.45 -0.04 -0.54
Enterprise Value (EV)		 4.85 0.00 4.77 7.32 0.35 1.45 0.52 -0.98 -0.77 -0.53 -0.42
Market Capitalization		 4.85 0.00 7.91 8.80 2.80 3.70 2.94 1.24 1.02 0.97 2.44
Book Value per Share		 $0.00 $0.82 $0.60 $0.33 $0.50 $0.32 $0.22 $0.21 $0.19 $0.19 $0.21
Tangible Book Value per Share		 $0.00 $0.82 $0.60 $0.33 $0.50 $0.32 $0.22 $0.21 $0.19 $0.19 $0.21
Total Capital		 0.00 4.20 3.55 2.21 3.57 3.03 2.53 2.50 2.40 2.21 2.42
Total Debt		 0.00 0.18 0.10 0.11 0.24 0.15 0.08 0.09 0.19 0.12 0.06
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -3.10 -3.14 -1.48 -2.46 -2.24 -2.42 -2.22 -1.79 -1.50 -2.86
Capital Expenditures (CapEx)		 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.78 0.21 0.45 0.73 0.50 -0.03 0.16 0.37 0.57 -0.51
Debt-free Net Working Capital (DFNWC)		 0.00 4.06 3.44 2.04 3.43 2.89 2.46 2.46 2.35 2.18 2.41
Net Working Capital (NWC)		 0.00 3.87 3.35 1.93 3.19 2.74 2.38 2.38 2.16 2.06 2.35
Net Nonoperating Expense (NNE)		 0.11 0.30 0.44 0.42 0.12 0.15 0.14 0.02 0.06 0.04 -0.05
Net Nonoperating Obligations (NNO)		 0.00 -3.10 -3.14 -1.48 -2.46 -2.24 -2.42 -2.22 -1.79 -1.50 -2.86
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.01 0.02 0.03 0.01 0.01 0.01 0.01 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 14.07% 3.40% 6.30% 9.43% 6.22% -0.42% 1.96% 4.92% 7.83% -6.74%
Debt-free Net Working Capital to Revenue		 0.00% 73.54% 56.66% 28.86% 44.27% 36.23% 30.37% 30.56% 31.28% 30.17% 31.51%
Net Working Capital to Revenue		 0.00% 70.19% 55.03% 27.24% 41.17% 34.32% 29.44% 29.48% 28.76% 28.56% 30.69%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.16) ($0.22) ($0.21) ($0.06) ($0.01) ($0.04) ($0.01) ($0.02) ($0.01) $0.02
Adjusted Weighted Average Basic Shares Outstanding		 0.00 4.88M 6.50M 6.60M 7.26M 7.55M 11.59M 11.94M 11.94M 11.85M 11.94M
Adjusted Diluted Earnings per Share		 $0.00 ($0.16) ($0.22) ($0.21) ($0.06) ($0.01) ($0.04) ($0.01) ($0.02) ($0.01) $0.02
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 4.88M 6.50M 6.60M 7.26M 7.55M 11.59M 11.94M 11.94M 11.85M 12.78M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 5.73M 6.42M 6.61M 8.97M 11.31M 11.34M 11.34M 11.34M 11.34M 11.34M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.24 -0.69 -1.01 -0.97 -0.30 -0.35 -0.33 -0.04 -0.16 -0.09 0.13
Normalized NOPAT Margin		 -15.18% -39.08% -57.68% -49.41% -13.32% -17.50% -17.84% -2.27% -9.63% -5.48% 5.88%
Pre Tax Income Margin		 -22.41% -56.35% -82.58% -70.58% -18.53% -25.14% -25.42% -3.27% -13.38% -7.76% 10.60%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -24.19 -106.76 -354.17 -372.85 -189.28 -90.75 -146.59 -16.37 -121.87 -31.71 77.57
NOPAT to Interest Expense		 -16.93 -74.73 -247.92 -260.99 -132.50 -63.53 -102.61 -11.46 -85.31 -22.20 77.57
EBIT Less CapEx to Interest Expense		 -24.19 -106.76 -355.55 -374.32 -189.28 -90.75 -146.59 -16.37 -121.87 -31.74 77.57
NOPAT Less CapEx to Interest Expense		 -16.93 -74.73 -249.30 -262.47 -132.50 -63.53 -102.61 -11.46 -85.31 -22.22 77.57
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Syra Health’s latest quarter showed meaningful top-line growth and a return to profitability, but the longer-term picture still reflects a company that is highly dependent on working-capital swings and financing support.

For Q1 2026, revenue rose to $2.27 million from $1.73 million in Q4 2025 and $1.69 million in Q3 2025. Gross profit also improved to $971 thousand, and the company reported net income of $241 thousand, a notable improvement from recent losses.

Cash flow was also strong in the quarter, with $1.36 million in operating cash flow. That helped lift cash and equivalents to $2.92 million at March 31, 2026, up from $1.98 million at the end of Q3 2025.

That said, investors should not overlook the structural risks. Syra Health still carries a relatively small equity base, negative retained earnings, and limited long-term asset support. The business has also shown a history of inconsistent quarterly profitability and reliance on debt and capital structure changes to manage liquidity.

  • Q1 2026 revenue grew to $2.27 million, up sequentially from recent quarters.
  • Gross profit improved to $971 thousand, showing better operating leverage than in Q4 2025.
  • The company posted net income of $241 thousand, a turnaround from the prior quarter’s loss.
  • Operating cash flow was strong at $1.36 million in Q1 2026.
  • Cash and equivalents increased to $2.92 million, providing a healthier near-term liquidity buffer.
  • Debt was reduced by $54 thousand in Q1 2026.
  • Accounts receivable stood at $869 thousand, which is sizable relative to quarterly revenue and worth watching.
  • Total liabilities were $1.58 million versus $2.36 million in equity at quarter-end.
  • Retained earnings remained deeply negative at -$9.48 million, reflecting accumulated losses.
  • Results have been volatile, with quarterly net income swinging from losses to profit over the past several periods.

Looking at the broader trend, Syra Health’s revenue has generally stayed in the $1.7 million to $2.3 million range per quarter over the last year, but profitability has been uneven. Q1 2025 was a large loss, Q2 and Q3 2025 were also negative, and Q1 2026 was a sharp improvement.

Expense control appears to be the key swing factor. In Q1 2026, operating income was $191 thousand, compared with an operating loss of $136 thousand in Q4 2025 and $232 thousand in Q3 2025. That suggests the company can reach profitability when revenue is strong and operating costs stay contained.

However, the balance sheet does not yet look like one of a mature, heavily capitalized business. Total assets were just $3.94 million, with only modest noncurrent assets of $11 thousand and a large portion of the asset base tied up in current items like receivables and cash.

Bottom line: Syra Health’s latest quarter was encouraging, especially on revenue growth, profitability, and cash generation. But the company remains a small, volatile name, and investors should watch whether the Q1 2026 improvement is sustainable or just a short-lived bounce.

07/29/26 06:03 AM ETAI Generated. May Contain Errors.

Syra Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Syra Health's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Syra Health's net income appears to be on a downward trend, with a most recent value of -$896.33 thousand in 2025, falling from -$2.12 million in 2022. The previous period was -$3.76 million in 2024.

Syra Health's total operating income in 2025 was -$904.32 thousand, based on the following breakdown:
  • Total Gross Profit: $2.49 million
  • Total Operating Expenses: $3.39 million

Over the last 3 years, Syra Health's total revenue changed from $5.62 million in 2022 to $7.23 million in 2025, a change of 28.6%.

Syra Health's total liabilities were at $674.74 thousand at the end of 2025, a 15.7% decrease from 2024, and a 58.1% decrease since 2022.

In the past 3 years, Syra Health's cash and equivalents has ranged from $3.34 thousand in 2022 to $3.28 million in 2023, and is currently $1.61 million as of their latest financial filing in 2025.

Over the last 3 years, Syra Health's book value per share changed from 0.23 in 2022 to 0.19 in 2025, a change of -20.8%.


Related Companies

Financial statements for NASDAQ:SYRA last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel